Shares of Q32 Bio Inc. (NASDAQ:QTTB) were trading at $20.22, up $9, or 80%, on positive 36-week top-line results in severe or very severe alopecia areata (AA) from part B of the Signal-AA phase IIa trial evaluating bempikibart (bempi). The drug is a fully human anti-IL-7R-alpha antibody designed to re-regulate adaptive immune function by blocking IL-7 and thymic stromal lymphopoietin signaling. Mizuho analyst Joseph Catanzaro noted in a report that bempi “comfortably exceeded” the level of efficacy hoped for with the Severity of Alopecia Tool 20 (SALT20) rate: 40% in the modified intent-to-treat (mITT), with 30% in the ITT group. Catanzaro had expected 15-20% on the SALT20 measure, although more recent targets landed in the 25-30% range for the prospect from Waltham, Mass.-based Q32.

Korea targets generics, innovation in drug pricing overhaul

South Korea is moving ahead with its biggest reform of drug review and pricing in more than a decade, reflecting a wider shift across Asian markets to reward innovation and tighten controls on generics. The Health Insurance Policy Deliberation Committee of the Ministry of Health and Welfare on March 26, 2026, approved the policy changes set to take effect starting in the second half of the year, coming after months of public-private deliberations that launched on Nov. 28, 2025. Seong Hoon, senior manager of strategy, risk and transactions at Deloitte Korea, told BioWorld that the large-scale institutional reform is likely to spur a transition from a generic-centered, quantitative growth structure to a qualitative one focused on innovation in the domestic industry. “The reform is significant because it goes beyond simple price adjustments,” Seong said, and “signals an attempt to strike a new balance between growing pressures on the national health insurance and innovation in the pharmaceutical industry.”

AAIC 2026: Age of amyloid is being joined by time of tau

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around tau. The presentation of data from the phase II Celia trial of tau-lowering diranersen, which is coming up on Tuesday, was called “probably the most anticipated paper at AAIC” on a preview call of the meeting hosted by Cantor. Sunday’s plenary speaker Ryan Watts, CEO of Denali Therapeutics Inc., highlighted tau-lowering agents as being among the most exciting themes of the conference. “At this conference, we’re going to see additional clinical data that may validate [tau as] a second target in Alzheimer’s disease, amyloid being the first,” he told the audience. The Celia trial, though, is something of the tip of the iceberg. Or the pyramid. Or the spear. Whatever one’s preferred metaphor, so far the main increase in tau therapeutics development is in earlier stages.

UK to launch Alzheimer patient database to speed up trials

The U.K. is setting up a nationwide registry of people with dementia, who will be pre-screened and consented, to speed up recruitment to clinical trials and collect real-world evidence of effectiveness once therapies are approved. At the core of the initiative is the adoption of pTau217 blood biomarker tests, which, combined with digital cognition assessments, now enable pre-screening and monitoring. This dual approach offers a scalable, lower-cost and more patient-friendly alternative to invasive PET scans or cerebrospinal fluid analyses currently used to screen patients when they are recruited into clinical trials. It is expected to improve the identification of people at risk, support regulatory alignment and reduce trial failure rates. The initiative, called the Brain Aging Registry for Biomarkers, Access to trials, Research and Adoption (BARBARA), has government funding and involves companies, health foundations, academics and the National Health Service.

Zeta secures FDA clearance for TMS robotic system

Zeta Surgical Inc. received U.S. FDA 510(k) clearance for its transcranial magnetic stimulation (TMS) robotic system, which is designed to support precise and repeatable TMS therapy for patients with treatment-resistant depression. Cleared as a class II stereotaxic instrument, the technology provides real-time navigation, robotic coil positioning and automatic motion compensation to keep stimulation targeted even when patients move during treatment. The clearance brings another TMS navigation system to the market to help with accurate targeting of treatment sites to help with therapy delivery.

China’s Mindrank raises $52M series B to advance oral GLP-1

Mindrank AI Ltd. completed a $52 million series B round to advance MDR-001, its AI-discovered oral small-molecule GLP-1 receptor agonist, which is in phase III trials for obesity in China. MDR-001, developed using Mindrank’s Molecule Pro AI platform, is one of the first AI-designed molecules to reach phase III, advancing from project initiation to late-stage testing in about 4.5 years. The Hangzhou, China-based company said cumulative R&D investment from the start of the program through phase III initiation was about $23 million. The financing will also support continued development of Mindrank’s Molecule Arts Platform (MAP), which combines multi-agent AI systems, generative molecular design, computational biology, experimental validation and clinical learning in a unified drug discovery platform. By integrating AI across the R&D workflow, Mindrank aims to make drug discovery and development faster, more scalable and more predictable.

Fed Circuit once again instructs on enablement of Rx claims

A federal jury was wrong when it determined that Astrazeneca plc should pay a Pfizer Inc. unit $107.5 million in damages for infringing two cancer patents, the U.S. Court of Appeals for the Federal Circuit said in a precedential decision last week. The appellate court agreed with the lower court that overturned the jury award after finding the patents were invalid for lack of enablement. Besides being a win for Astrazeneca, the Fed Circuit ruling serves as yet another case study on enablement when a drug patent claims a broad scope of compounds or, in this instance, encompasses an extensive range of dosages.

Takeda's mezagitamab adds quality-of-life gains to ITP responses

Takeda Pharmaceutical Co. Ltd.’s anti-CD38 antibody mezagitamab (TAK-079) is showing benefits beyond platelet restoration, with new data suggesting the candidate may improve quality of life for patients with chronic immune thrombocytopenia (ITP) and sustain those gains after treatment ends. Presented at the International Society on Thrombosis and Haemostasis Congress on July 12, the phase II findings add to mezagitamab’s profile as Takeda advances the antibody into phase III development in ITP. The company is positioning the therapy as a potential disease-modifying treatment that could reset the immune dysfunction driving the disease, rather than simply control platelet numbers.

FDA advances streamlined Rx registration path

The U.S. FDA is proposing changes to streamline its drug establishment registration regulations for distributed biopharma manufacturing facilities and to strengthen the country’s drug supply chain. “The proposed changes would make it easier for innovative manufacturers to operate efficiently, and give the FDA a clearer, more accurate picture of how and where drugs are being made,” said Michael Davis, acting director of CDER. Incorporating statutory changes made by the Prevent Pandemics Act, the proposed rule, if finalized, is expected to reduce registration costs for distributed manufacturing companies and create long-term efficiencies for industry and the agency, according to the FDA.

Also in the news

Absentia Labs, Bausch + Lomb, C2N, Cue, Freenome, GSK, Hansoh, Innocare, Leads Biolabs, Leo, Moderna, Pegbio, Pharmnovo, Precisio Biotix, Rani, Roche, Sanofi, Silo, SL Science, Swedish Orphan, Tibaray, Xvivo